Full approval was driven by BREAKWATER Phase III outcomes, including PFS HR 0.53 and OS HR 0.49 versus fluoropyrimidine/oxaliplatin-based chemotherapy options ± ...

Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored anti-PD-1 response in resistant melanoma models. The strategy could expand ...

Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be ...

KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with ...

(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 25 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...